Cohort Construction and Prognostic Model Construction for Multiple Myeloma

N/AActive Not RecruitingNCT06366802

The First Affiliated Hospital of Soochow University1,000 enrolled

Overview

Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations. How to construct a clinical prognosis model of MM through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. It is necessary to build an MM-specific cohort in China to comprehensively understand the characteristics of MM patients, explore treatment options, and improve prognostic factors for survival outcomes.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Multiple Myeloma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Patients were diagnosed as multiple myeloma from January 1, 2008 (the diagnostic criteria are based on "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (Revised in 2020)"). Exclusion Criteria: Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Outcomes

Primary Outcomes

Overall survival

Overall survival is defined as the time from being treated to death from any cause.

Time frame: 5 years

Secondary Outcomes

Progression free survival(PFS)

Progression-free survival (PFS) is defined as the time from being treated to disease progression or death from any cause.

Time frame: 5years